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AIM—To examine the influence of gynecologic oncologists (GO) in the United States on surgical/
chemotherapeutic standard of care (SOC), and how this translates into improved survival among 
women with ovarian cancer (OC).
METHODS—Surveillance, Epidemiology, and End Result (SEER)-Medicare data were used to 
identify 11688 OC patients (1992–2006). Only Medicare recipients with an initial surgical 
procedure code (n = 6714) were included. Physician specialty was identified by linking SEER-
Medicare to the American Medical Association Masterfile. SOC was defined by a panel of GOs. 
Multivariate logistic regression was used to determine predictors of receiving surgical/
chemotherapeutic SOC and proportional hazards modeling to estimate the effect of SOC treatment 
and physician specialty on survival.
RESULTS—About 34% received surgery from a GO and 25% received the overall SOC. One-
third of women had a GO involved sometime during their care. Women receiving surgery from a 
GO vs non-GO had 2.35 times the odds of receiving the surgical SOC and 1.25 times the odds of 
receiving chemotherapeutic SOC (P < 0.01). Risk of mortality was greater among women not 
receiving surgical SOC compared to those who did [hazard ratio = 1.22 (95%CI: 1.12–1.33), P < 
0.01], and also was higher among women seen by non-GOs vs GOs (for surgical treatment) after 
adjusting for covariates. Median survival time was 14 mo longer for women receiving combined 
SOC.
CONCLUSION—A survival advantage associated with receiving surgical SOC and overall 
treatment by a GO is supported. Persistent survival differences, particularly among those not 
receiving the SOC, require further investigation.
Keywords
Ovarian neoplasms; Gynecologic oncologist; Guidelines-based care; Surveillance; Epidemiology; 
and End Result Medicare
INTRODUCTION
Women in the United States with advanced stage epithelial ovarian cancer (OC) have an 
overall 5-year survival rate of about 30%[1]. As with many cancers, survival is closely linked 
with the stage of diagnosis, such that women with localized (stage I) disease have a relative 
5-year survival rate of 92%; the prognosis however declines with late stage disease and 
metastases[2]. Without an adequate early detection strategy, ensuring that women receive 
appropriate, standard of care (SOC) treatment is a very important intervention that has 
demonstrated reduction in OC mortality[3].
National Comprehensive Cancer Control Network (NCCN) current treatment 
recommendations for women with epithelial OC include an evaluation prior to initiating 
chemotherapy along with accurate surgical staging and primary debulking surgery/
cytoreduction performed by a gynecologic oncologist (GO)[3]. In most but not all cases, at 
least six cycles of platinum and taxane-based chemotherapy administration is recommended 
for advanced epithelial OCs[3]. Appropriate care not only constitutes the receipt of SOC 
treatment, but also quality care from an experienced GO, who is trained to both perform the 
surgery and administer chemotherapy[3,4]. The evidence supporting better guideline-
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adherent care and outcomes among patients seen by a GO has been previously 
examined[5–8], and prior studies suggest only 30%–40% of women with OC are treated by a 
GO[5,9–11]. While NCCN cancer center patients tend to receive guideline-adherent care[12], 
there is potential in exploring whether differences in SOC treatment are affected across 
patient-level demographic and clinical subgroups.
To date, few studies have jointly considered surgical and chemotherapeutic SOC indicators 
in examining survival in OC patients[13–17]. In this study, we examine predictors of both 
SOC receipt (surgical and chemotherapeutic) and adherence to these treatments among 
women treated by GOs compared to non-GOs. We further quantified the survival advantage 
of SOC treatment receipt among OC patients.
MATERIALS AND METHODS
Data source and study population
The study included all women in the Surveillance, Epidemiology, End Results (SEER)-
Medicare database[18] diagnosed with OC from January 1, 1992 to December 31, 2006 (n = 
38972). We excluded women who did not have a primary epithelial OC diagnosis (n = 
6175); were Medicare age-ineligible (age < 66) at date of diagnosis (n = 11716); had an 
invalid month of diagnosis (n = 166); had diagnoses based on autopsy or death certificate 
only (n = 543); had a nonepithelial ovarian malignancy (n = 3198); and were not 
continuously enrolled in both Medicare Part A and B or were enrolled in an Health 
Maintenance Organization plan during the course of treatment (n = 5486). A total of 11688 
OC patients met the inclusion criteria for the study.
Definition of variables
Patient-level covariates included age, race, stage at diagnosis, marital status, year of 
diagnosis, geographic region of SEER registry, and cancer histology. The Charlson-
Klabunde comorbidity index score was determined using Medicare claims data for 12 mo 
prior to and 4 mo after cancer diagnosis date, per prior studies[19,20].
We examined all procedure codes in the Medicare claims data falling within a treatment 
window (defined as two months prior to and one year after the diagnosis date) to determine 
if a patient received surgical or chemotherapeutic SOC. Since only month and year of 
diagnosis are reported in the SEER database, the 15th day of the month was assigned as the 
day of diagnosis for each patient.
SOC definitions
Per recommendation from an experienced group of GOs, consulted specifically for this 
project (W. Brewster, R.E. Bristow and D.K. Singh), the International Federation of 
Gynecologists and Obstetricians (FIGO) stage of disease categories were grouped as: I A/I 
B, I C/II, IIIA/III B and IIIC/IV based on similarities in current surgical and 
chemotherapeutic treatment regimens. FIGO stage III NOS and stage IV were grouped into 
stage IIIC/IV group, given that a high proportion of all stage III cases were stage IIIC.
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Among the women who met the inclusion criteria (n = 11688), we examined receipt of SOC 
among women receiving any initial surgical care. Thus, we further excluded women who 
received treatment outside of the treatment window (n = 28), those who had no procedure 
codes of interest for any surgical care (n = 2464), and women who received neoadjuvant 
chemotherapy (n = 2482) (given the difficulty of cancer staging for women who are eligible 
for neoadjuvant chemotherapy) to examine differences in guideline-adherent treatment and 
survival. We also excluded all OC patients diagnosed with stage I NOS or who were 
unstaged at diagnosis since minimum SOC parameters are not well defined for these groups.
The GO group defined minimum surgical SOC as lymph node dissection, omentectomy and 
oophorectomy for all patients with FIGO stage IA/IB, IC/II or IIIA/IIIB at diagnosis, but 
omentectomy and oophorectomy only for women with stage IIIC/IV at diagnosis. Minimum 
chemotherapy SOC definition depended on: (1) stage of disease at diagnosis; (2) number of 
chemotherapy cycles received; and (3) type of chemotherapy agent received. For analysis, 
chemotherapy SOC was defined as an individual receiving the defined number of cycles 
(three cycles of chemotherapy for stage IC/II and six cycles for stage III/IV), with at least 
one multi-agent cycle (defined as one platinum based and one non-platinum based agent) 
using either intravenous or intraperitoneal modes of administration. One cycle of 
chemotherapy was equal to three weeks of treatment, given that chemotherapy is usually 
administered every 3–4 wk[3,21]. Patients were documented as receiving overall SOC if they 
received both surgical and adjuvant chemotherapeutic SOC.
The GO group recommended surgical and chemotherapy procedure codes for use in 
determining SOC for each FIGO stage category. Procedure codes included both International 
Classification of Diseases, Ninth revision, clinical modification codes and American 
Medical Association (AMA) Current Procedural Terminology codes.
Surgeon specialty definition
Self-reported, physician specialty information from the SEER-Medicare claims file was 
linked with and verified against the AMA Physician Masterfile using the unique provider 
identification number (UPIN) for physicians performing (or those in attendance) of an OC 
procedure of interest. If the operating physician UPIN was not available, but the attending 
physician UPIN was available, AMA specialty was assigned to the attending physician. If 
the UPIN for an operating and attending physician was unavailable, the self-reported 
physician specialty variable found in the Medicare data set was used to define specialty. 
When a patient received treatment from multiple physicians, care was attributed to the most 
specialized physician (most to least specialized: GO, gynecologist, general surgeon, and 
other physician). For analytic purposes, physician specialty was grouped as GO and non-
GO.
Statistical analysis
We examined predictors associated with receipt of surgical and chemotherapeutic SOC. A 
forward selection logistic regression model was used to examine each question. 
Comparisons of the distribution of OC patients receiving the SOC by physician specialty 
was examined using the Pearson χ2 test.
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Cox proportional hazard methods were used to determine differences in survival time from 
date of OC diagnosis to date of death. The proportional hazards assumption was examined 
by testing interactions between time and each covariate in the model. The final models 
(Model 1 and 2) exclude women (n = 1003) who died within 4.5 mo after diagnosis (i.e., 
women who did not live long enough to receive chemotherapy SOC). Due to a common 
category in the chemotherapy variables (chemotherapy SOC and chemotherapy physician 
specialty), we examined two different models. The first model (Model 1) examined surgery 
physician specialty and receipt of both SOC measurements, while the second model (Model 
2) examined both surgery and chemotherapy physician specialty and receipt of surgery SOC, 
adjusting for patient-level and clinical factors. All final models were adjusted for covariates 
that had a statistically significant association from the bivariate analysis or were of 
importance in the literature. All analyses were performed using SAS version 9.3 (SAS 
Institute Inc., Cary, NC, United States).
RESULTS
Among the 11688 OC patients, 57.4% (n = 6714) received an initial surgical procedure code 
of interest. Table 1 shows the patient and tumor characteristics by the type of physician 
performing the initial surgery. The mean age of patients was mid to late-70s; most women 
were white, married or widowed, had no comorbidities, had FIGO stage IIIC/IV disease, and 
serous histology. More women received an initial surgical procedure from OB/GYNs (n = 
3088) than GOs (n = 2254), general surgeons (n = 914), or other non-GO/unknown 
specialties (n = 419).
Among women treated by a GO, 79.2% received the surgical SOC and 52.8% received the 
chemotherapy SOC (Figure 1). Regardless of stage at diagnosis, women more frequently 
received surgical and chemotherapeutic SOC from a GO than from a non-GO.
Table 2 reports the factors associated with receipt of surgical SOC after adjusting for other 
covariates. Surgery performed by a GO was strongly associated with receiving surgical SOC 
[odds ratio (OR) for GO = 2.35; 95%CI: 2.03–2.71]. Other factors associated with greater 
odds of surgical SOC receipt included: More advanced stage of disease, white vs African-
American race, younger age at diagnosis, serous vs adenocarcinoma not otherwise specified 
histologic type, being married vs not married, and diagnosis during the later years of the 
study period.
Table 2 also reports factors associated with receipt of the minimum chemotherapy SOC after 
adjusting for other covariates. Women who obtained chemotherapy from a GO had a higher 
odds of receiving chemotherapeutic SOC (OR = 1.25, 95%CI: 1.07–1.47). Other statistically 
significant factors for higher odds of chemotherapeutic SOC included: Less advanced stage 
of disease, younger age at diagnosis, histologic type (serous compared with endometrioid/
mucinous/clear cell), being married compared with unmarried, living in the SEER Midwest 
region (compared to the SEER Northeast), and diagnosis during more recent years.
Table 3 shows the Cox regression model of time to death among the sample of OC patients 
who received a primary surgery procedure who did not die within 4.5 mo after diagnosis. In 
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Table 3 (Model 1), women who did not receive surgery SOC had increased mortality 
compared to women who did [hazard ratio 1.22 (95%CI: 1.12–1.33)]. Similarly, women who 
did not receive any chemotherapy SOC had a higher risk of earlier death compared to 
women who received the full contingent of chemotherapy [hazard ratio 1.29 (95%CI: 1.14–
1.46)]. Increasing age, late stage disease, higher number of comorbidities, and mucinous 
histology compared to serous histology were all associated with increased death (Table 3, 
Model 1). Similar patterns were observed in Table 3, Model 2 after controlling for 
chemotherapy physician specialty (as opposed to chemotherapy SOC). For Model 2, women 
who received surgery from a GO had better survival. Although there was no significant 
difference in survival between chemotherapy treatment from a GO compared to non-GO, 
those not receiving any chemotherapy had a significantly shorter survival time (Table 3, 
Model 2). The median survival time for women who received the overall SOC was 52 mo 
compared to 38 mo for women that did not receive the overall surgical and chemotherapeutic 
SOC (Figure 2).
DISCUSSION
Our findings show that among OC patients receiving initial surgical treatment, only 25% of 
women received the overall SOC as defined by our panel of GOs. Few women 
(approximately one-third of women receiving a surgical procedure) had a GO involved at 
any point during their care. Women who obtained surgery from a GO however, were more 
likely to receive the surgical SOC and chemotherapeutic SOC than women who obtained 
treatment from a non-GO. The median survival time was 14 mo longer for women who 
received the overall SOC compared to women who did not receive overall SOC.
Our results are consistent with prior studies that suggest that appropriate surgical treatment 
in the United States is more frequently performed when a GO is the treating physician[5]. 
Data from a single state cancer registry study by Chan et al[14] showed that women with OC 
under the care of GOs were more likely to receive appropriate staging and chemotherapy 
treatments, controlling for age, stage, and grade of disease. Also similar to previous studies, 
our results suggest that greater utilization of GOs in the care of OC patients would be 
beneficial[22]. Although the level of detail in our analysis is unable to discriminate the 
factors underlying the low utilization, it is likely that our results reflect a complex interaction 
of both preference and access-relevant effects, such as the influence of a patient’s choice in 
receipt of GO care vs a shortage of available GOs in some areas.
While patient treatment preferences can independently and significantly affect chemotherapy 
receipt[23], geographic access may also play an important role in (both chemotherapeutic or 
surgical) treatment receipt from a GO. For example, a previous analysis reported on the 
unequal distribution of GOs in the United States[24]. A recently published study suggested 
that OC mortality may be a function of distance to a practicing GO as counties located more 
than 50 miles from a gynecologic oncology practice had almost 60% increased likelihood of 
OC mortality than those physically closer to a practice location[25]. While earlier research 
efforts have indicated that treatment of OC can be improved by early referral to a GO[5,10], 
referral and consultation from GOs have generally been low, with only about 39% of family 
physicians and 51% of general internists self-reporting referrals to a GO[26]. Given that 
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surgery is an important determinant of outcomes for OC patients, receiving surgery/
treatment from surgeons with specialized training in pelvic surgery (i.e., GOs)[27], who see a 
high volume of cases[10,28] at high volume facilities treating more than 20 OC cases per 
year[28,29], might help improve outcomes.
It is important to note that there are still subgroups that require further research. Although 
African-American women were more likely than their white counterparts to receive their 
initial surgical procedure from a GO (data not shown), they had lower odds of receiving the 
surgical SOC and there was no difference in survival after adjusting for physician specialty, 
surgical SOC, and other tumor and sociodemographic characteristics. The increased risk of 
death among African American women noted in other studies, when controlling for receipt 
of chemotherapeutic SOC, suggests that there may be some important nuanced differences 
in the definitions of chemotherapeutic SOC[30,31], chemotherapeutic agents, and/or 
interaction effects between age, comorbidity, stage, and race that have not been adequately 
explored. Bristow et al[32] have previously suggested similar differences in survival between 
African-American and white OC patients and the complexity of examining race-based 
survival associations[33,34].
The findings in this study should be considered in light of several limitations: (1) our 
analysis was focused on fee for service Medicare; women who received treatment under 
managed care were not included because the managed care cases did not include codes to 
identify specific treatment procedures; (2) neoadjuvant chemotherapy cases, which could 
have later received surgical SOC, were excluded; and (3) it is a challenge to operationalize 
NCCN recommendations into an analytic/computer program because the recommendations 
are relatively complex, and some information required for the NCCN decision algorithms is 
not available in claims data. However, our panel of experienced GOs developed a simpler, 
but accurate definition of the SOC so that recommendations could be converted into analytic 
code. Similarly, since SOC definitions were varied for each stage at diagnosis, if claims data 
were not available for the full contingency of treatment procedures, it is possible that there 
was an underestimation of patients identified as receiving overall SOC in that subgroup. 
Fourth, given the limitations of Medicare data, inaccuracies or incomplete data in billing, 
drug, or procedure codes could have resulted in an underestimate or overestimate of the total 
number of surgeries and/or chemotherapy procedures performed, thus biasing the estimate. 
Previous studies have noted some concerns in the validation of chemotherapeutic agents 
within Medicare claims data[30,31]. Fifth, there is potential for misclassification of physician 
specialty, given the use of multiple data sources including operating physician, attending 
physician, and self-reported physician specialty[35]. Furthermore, in our analysis, receipt of 
treatment from a GO was designated as such if a GO had been seen at any point during the 
care. Lastly, since we assumed each cycle of treatment lasted three weeks, we calculated that 
it would take at least 4.5 mo for women diagnosed with stage IIIC or IV to complete the 
chemotherapy SOC as defined in our study. Thus, women who died within five months of 
the diagnosis date would not have had the opportunity to receive chemotherapy SOC. Our 
definition of chemotherapy SOC may have been too rigorous and potentially introduce 
selection or survival bias.
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Our study showed that GOs more often provided the surgical and chemotherapeutic SOC. 
The receipt of surgical standards was associated with better survival outcomes, even after 
adjusting for provider specialty. As such, these two NCCN-recommendations (i.e., treatment 
from a GO and receipt of SOC) continue to be critical points of intervention for improving 
survival time and reducing deaths from OC. Although it is difficult to determine when 
adjuvant chemotherapy is warranted based on sound clinical judgement (i.e., taking into 
consideration the patient’s comorbidities, toxicities, age, etc.) or patient refusal, one area 
that has not been carefully examined is the potential that race/ethnicity-based differences in 
patient and caregiver preferences may have for OC care. Future research may further explore 
this and the interaction effects of race, age, comorbidities on survival.
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COMMENTS
Background
Ovarian cancer (OC) is the deadliest gynecologic cancer among women. Standard 
treatment for OC consists of extensive surgery and chemotherapy. Gynecologic 
oncologists (GOs) more often adhere to standard treatment guidelines among OC 
patients, resulting in longer patient survival.
Research frontiers
Low survival rates from OC may be related to lack of GO involvement in surgery or 
chemotherapy and/or lack of standard treatment receipt. Research measuring receipt of 
standard of care and its effect on survival can help reveal areas for intervention to 
improve OC mortality.
Innovations and breakthroughs
These results among over 6000 OC patients aged 65 and older indicate that a low 
proportion received standard treatment. Not having seen a GO, African American race, 
and being older (80+) were associated with not receiving standard treatment. Women 
who received standard treatment survived over one year longer than those who did not 
receive standard treatment.
Applications
Ensuring appropriate referral of OC patients to GOs for treatment will likely increase 
survival rates from OC. Education of primary care providers and/or health systems 
changes that promote referral would be beneficial to increase referral rates. Research is 
needed into patient factors and other potential reasons underlying lack of referral.
Terminology
GOs are subspecialists trained to administer both surgical and chemotherapeutic 
treatment to OC patients.
Peer-review
The authors investigated the influence of GO in the United States on surgical/
chemotherapeutic SOC, and how this translates into improved survival among women 
with OC. The authors claimed that a survival advantage is associated with receiving 
surgical SOC and overall treatment by a GO. This manuscript provides useful 
information to the medical students, clinicians, and researchers in this field.
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Figure 1. Surgical standard of care (n = 4434) and adjuvant chemotherapy standard of care (n = 
2595) receipt by physician specialty and International Federation of Gynecologists and 
Obstetricians stage
(1) Surgery SOC treatment was based on ovarian cancer patients receiving surgery prior to 
chemotherapy (n = 6714); (2) Stages 1, not otherwise specified and Unknown/unstaged were 
removed from analysis; (3) Surgeon specialty and chemotherapy specialty was categorized 
according to the most specialized care received during the course of the treatment window; 
(4) Women who received surgery SOC by a surgeon specialty who could not be identified 
are not shown (n = 17); (5) There were 177 women who received a chemotherapy procedure 
code of interest but for whom physician specialty could not be identified and 1238 women 
who did not receive a chemotherapy procedure code of interest.1 Denote that the estimate is 
statistically significantly higher for GO compared to Non-GO. SOC: Standard of care; GO: 
Gynecologic oncologist.
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Figure 2. Ovarian cancer survivor curves1 by receipt of overall standard of care2 (n = 1678)
1All covariates held at the reference level noted in Table 3; 20 = Did not receive overall 
standard of care; 1 = Did receive overall SOC. SOC: Standard of care.
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Table 1
Characteristics of ovarian cancer patients who received any initial surgical procedure by physician specialty (n 
= 6714)
Characteristic Surgeon specialty1
GO Non-GO
OBGYN General surgeon Other2
No. of patients 2254 3088 914 419
Mean age at diagnosis (stddev) 74.6 (5.9) 74.8 (6.1) 77.0 (6.8)    75.5 (6.2)
Race n (%)
 White 1995 (88.5) 2844 (92.1) 827 (90.5) 379 (90.5)
 African American 121 (5.4) 104 (3.4) 49 (5.4) 26 (6.2)
 Hispanic   35 (1.6)   31 (1.0) 3 3
 Asian   53 (2.4)   66 (2.1) 3 3
 Other4   47 (2.1)   37 (1.2) 3 3
Marital status
 Married 1052 (46.7) 1424 (46.1) 327 (35.8) 170 (40.6)
 Single 159 (7.1) 221 (7.2) 53 (5.8) 31 (7.4)
 Divorced 148 (6.6) 166 (5.4) 58 (6.3) 29 (6.9)
 Widowed   799 (35.4) 1168 (37.8) 458 (50.1) 176 (42.0)
 Separated/unknown   96 (4.2) 109 (3.5) 3 3
Charlson-Klabunde comorbidity score
 0 1521 (67.5) 2133 (69.1) 605 (66.2) 266 (63.5)
 1   498 (22.1)   644 (20.9) 188 (20.6)   93 (22.2)
 2 175 (7.8) 189 (6.1) 78 (8.5) 38 (9.1)
 3   45 (2.0)   80 (2.6) 29 (3.2) 3
 4 or more 3   42 (1.4) 3 3
FIGO treatment stage
 IA/IB 200 (8.9)   383 (12.4) 66 (7.2)   43 (10.3)
 IC/II   276 (12.2)   516 (16.7) 90 (9.8) 40 (9.5)
 IIIA/IIIB 119 (5.3) 179 (5.8) 59 (6.5) 3
 IIIC/IV 1580 (70.1) 1898 (61.5) 660 (72.2) 308 (73.5)
 Unstaged/NOS   79 (3.5) 112 (3.7) 39 (4.2) 3
Histology
 Serous 1460 (64.8) 1897 (61.4) 554 (60.6) 254 (60.6)
 Endometrioid   238 (10.6)   381 (12.3) 73 (8.0)   46 (11.0)
 Mucinous 129 (5.7) 235 (7.6) 79 (8.6) 25 (6.0)
 Clear cell   84 (3.7) 127 (4.1) 3 3
 Adenocarcinoma   275 (12.2)   344 (11.1) 175 (19.1)   66 (15.8)
 Other5   68 (3.1) 104 (3.3) 20 (2.2) 3
1Surgeon specialty was categorized according to the most specialized care received during the course of the treatment window
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239 women received a surgery procedure code during the treatment window (defined as a period of two months prior and one year after a patient’s 
diagnosis date in which procedures were performed) but surgeon specialty could not be identified
3
Denotes cell size suppression of less than 20
4Other race includes designation of “Other” or Native American
5Other histology includes Transitional. GO: Gynecologic oncologists; FIGO: International Federation of Gynecologists and Obstetricians; NOS: 
Not otherwise specified.
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Table 2
Predictors of receipt of minimum surgical and chemotherapeutic standard of care1
Surgical standard of care2 Chemotherapeutic standard of care2
Odds ratio (95%CI) P value Odds ratio (95%CI) P value
Physician specialty3
 Gynecologic oncologist 2.35 (2.03–2.71) < 0.01 1.25 (1.07–1.47)    0.006
 Non-gynecologic oncologist 1.00 1.00
Age at diagnosis
 66–69 1.00 1.00
 70–74 0.80 (0.67–0.96)    0.017 0.93 (0.78–1.09)    0.393
 75–79 0.83 (0.69–1.0)     0.053 0.79 (0.66–0.94)    0.008
 80–84 0.58 (0.47–0.71) < 0.01 0.61 (0.48–75)  < 0.001
 ⩾ 85 0.40 (0.31–0.51) < 0.01 0.31 (0.21–0.48) < 0.001
Race4
 White 1.00
 African American 0.67 (0.50–0.91)    0.01 –
 Other 0.83 (0.62–1.10)    0.208 –
Treatment stage5
 IA/IB 0.08 (0.07–0.10) < 0.01 NA    NA
 IC/II 0.08 (0.07–0.10) < 0.01 3.46 (2.86–4.18) < 0.001
 IIIA/IIIB 0.05 (0.04–0.07) < 0.01 0.83 (0.64–1.09)    0.182
 IIIC/IV 1.00 1.00
Charlson-Klabunde comorbidity score
 0 1.00 1.00
 1 0.84 (0.72–0.98)    0.029 0.84 (0.71–0.99)    0.029
 2 0.81 (0.63–1.02)    0.084 0.78 (0.60–1.03)    0.078
 3 0.65 (0.44–0.97)    0.039 0.49 (0.31–0.80)    0.005
 4 or more 1.09 (0.60–1.97)    0.771 0.63 (0.29–1.37)    0.247
Histology
 Serous 1.00 1.00
 Endometrioid 1.10 (0.90–1.35)    0.356 0.70 (0.56–0.89)    0.003
 Mucinous 0.95 (0.74–1.35)    0.67 0.49 (0.34–0.70) < 0.001
 Clear cell 1.29 (0.93–1.78)    0.13 0.62 (0.41–0.93)    0.026
 Transitional 0.70 (0.27–1.79)    0.454 0.76 (0.30–1.97)    0.572
 Adenocarcinoma (NOS) 0.44 (0.37–0.54) < 0.001 1.04 (0.86–1.27)    0.695
 Other 1.05 (0.70–1.56)    0.813 0.74 (0.47–1.13)    0.168
Marital status
 Married 1.00 1.00
 Not married 0.83 (0.72–0.95)    0.007 0.75 (0.66–0.86) < 0.001
 Unknown 1.03 (0.69–1.52)    0.87 0.73 (0.48–1.09)    0.127
Year of diagnosis
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Surgical standard of care2 Chemotherapeutic standard of care2
Odds ratio (95%CI) P value Odds ratio (95%CI) P value
 1993–1997 0.62 (0.52–0.73) < 0.01 0.28 (0.23–0.33) < 0.001
 1998–2002 0.79 (0.68–0.92)    0.003 1.09 (0.94–1.26)    0.261
 2003–2006 1.00 1.00
SEER region4
 Northeast – 1.00
 Midwest – 0.76 (0.62–0.93)    0.009
 South – 1.09 (0.88–1.37)    0.424
 West – 0.93 (0.78–1.10)    0.391
1
Minimum SOC treatment was based on patients receiving surgery prior to chemotherapy (n = 6714)
2Surgery SOC (n = 4434) and chemotherapy SOC (n = 2595)
3
Physician specialty was categorized according to the most specialized care received during the course of the treatment window; there were 39 and 
177 cases where physician specialty could not be identified for surgery or chemotherapy procedures, respectively (results for this group not shown)
4
Race was not entered into the chemotherapy SOC model based on forward selection entry criteria (P ≤ 0.10); Region was not entered into the 
surgery SOC model based on forward selection entry criteria (P ≤ 0.10)
5Stage I NOS, Stage IA/IB (for chemotherapy SOC) and unknown/unstaged were removed from the analysis since current guidelines recommend 
early stage patients not receive chemotherapy treatment. NOS: Not otherwise specified; SOC: Standard of care; SEER: Surveillance, Epidemiology, 
and End Result; NA: Not applicable.
World J Obstet Gynecol. Author manuscript; available in PMC 2018 March 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Rim et al. Page 18
Table 3
Cox proportional hazard model of time-to-death among ovarian cancer patients
Predictor Model 11 Model 21
Hazard ratio (95%CI) P value Hazard ratio (95%CI) P value
Received surgery SOC2
 Yes 1.00 1.00
 No 1.22 (1.12–1.33) < 0.01 1.21 (1.11–1.31) < 0.01
Received chemotherapy SOC2 4
 Yes 1.00 4
 No, but received some chemotherapy 0.95 (0.89–1.02) 0.18 4
 Received no chemotherapy 1.29 (1.14–1.46) < 0.01 4
Age at diagnosis
 66–69 1.00 1.00
 70–74 1.07 (0.98–1.17) 0.13 1.05 (0.97–1.15) 0.24
 75–79 1.23 (1.12–1.34) < 0.01 1.21 (1.10–1.32) < 0.01
 80–84 1.52 (1.37–1.69) < 0.01 1.48 (1.33–1.65) < 0.01
 ⩾ 85 1.96 (1.70–2.26) < 0.01 1.92 (1.67–2.21) < 0.01
Race
 White 1.00 1.00
 African American 1.11 (0.95–1.29) 0.18 1.13 (0.97–1.32) 0.12
 Other 0.90 (0.78–1.05) 0.17 0.88 (0.75–1.02) 0.09
Year of diagnosis
 1993–1997 1.27 (1.17–1.38) < 0.01 1.24 (1.14–1.35) < 0.01
 1998–2002 1.18 (1.09–1.27) < 0.01 1.17 (1.08–1.27) < 0.01
 2003–2006 1.00 1.00
Treatment stage
 IA/IB 0.20 (0.18–0.23) < 0.01 0.17 (0.15–0.20) < 0.01
 IC/II 0.35 (0.32–0.40) < 0.01 0.36 (0.32–0.40) < 0.01
 IIIA/IIIB 0.61 (0.53–0.71) < 0.01 0.62 (0.54–0.71) < 0.01
 IIIC/IV 1.00 1.00
Charlson-Klabunde comorbidity score
 0 1.00 1.00
 1 1.28 (1.18–1.38) < 0.01 1.26 (1.17–1.36) < 0.01
 2 1.38 (1.22–1.56) < 0.01 1.37 (1.21–1.55) < 0.01
 3 1.64 (1.34–2.00) < 0.01 1.64 (1.34–2.01) < 0.01
 ⩾ 4 2.33 (1.73–3.15) < 0.01 2.27 (1.67–3.09) < 0.01
Histology
 Serous 1.00 1.00
 Endometrioid 0.76 (0.68–0.85) < 0.01 0.75 (0.68–0.84) < 0.01
 Mucinous 1.22 (1.06–1.41) < 0.01 1.22 (1.06–1.41) < 0.01
 Clear cell 0.83 (0.69–1.00) 0.05 0.83 (0.69–1.00) 0.05
 Transitional 0.79 (0.47–1.31) 0.36 0.79 (0.48–1.32) 0.37
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Predictor Model 11 Model 21
Hazard ratio (95%CI) P value Hazard ratio (95%CI) P value
 Adenocarcinoma (NOS) 1.07 (0.98–1.18) 0.14 1.07 (0.97–1.17) 0.2
 Other 1.02 (0.82–1.28) 0.85 1.02 (0.82–1.28) 0.85
Marital status
 Married 1.00 1.00
 Not Married 1.07 (1.00–1.14) 0.05 1.07 (1.00–1.14) 0.05
 Unknown 1.00 (0.82–1.23) 0.97 0.99 (0.80–1.21) 0.89
Surgeon specialty3
 Non-GO 1.00 1.00
 GO 0.90 (0.84–0.96) < 0.01 0.90 (0.84–0.97) < 0.01
Chemotherapy specialty3
 Non-GO 4 1.00
 GO 4 0.98 (0.89–1.08) 0.68
 Did not receive chemotherapy 4 1.33 (1.19–1.47) < 0.01
1
Model 1 and Model 2: Includes OC patients who did not have an unknown FIGO stage at diagnosis, and survived at least 4.5 mo after diagnosis;
2
Minimum SOC procedure codes for surgery
3
Missing surgeon and physician specialty excluded from analysis
4
Excluded from the model based inclusion criteria. Chemotherapy SOC and chemotherapy physician specialty cannot be included in the same 
model because the common level of “did not receive chemotherapy” would introduce a singularity and prevent model convergence. OC: Ovarian 
cancer; SOC: Standard of care; GO: Gynecologic oncologist; FIGO: International Federation of Gynecologists and Obstetricians; NOS: Not 
otherwise specified.
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